EZH2 and lymphoma: SHR2554 was a highly selective EZH2 inhibitor that could be taken orally, showing good inhibitory activity against both Y641 mutant and wild-type EZH2 methyltransferase activity in diffuse large B-cell lymphoma cell lines. It also showed a high efficacy rate (69%) in EZH2-mutant lymphoma [75, 76].